OrbiMed’s VectivBio Holding AG Ordinary Shares VECT Stock Holding History

OrbiMed’s Portfolio VECT Stock Details VECT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-5,156,561	Closed	-$87.7M	–	145
2023 Q2	$87.7M	Hold	5,156,561	–	–	1.59%	19
2023 Q1	$43.9M	Sell	5,156,561 -1,850,300	-26%	-$15.3M	0.86%	39
2022 Q4	$60.7M	Buy	7,006,861 +533,300	+8%	+$4.29M	1.16%	30
2022 Q3	$38.8M	Hold	6,473,561	–	–	0.72%	52
2022 Q2	$35M	Buy	6,473,561 +1,142,857	+21%	+$6.15M	0.63%	48
2022 Q1	$25.1M	Buy	5,330,704 +106,900	+2%	+$559K	0.41%	59
2021 Q4	$25.6M	Buy	5,223,804 +100,500	+2%	+$495K	0.33%	73
2021 Q3	$39.6M	Hold	5,123,304	–	–	0.44%	63
2021 Q2	$59.7M	Buy	+5,123,304	New	+$77.8M	0.6%	49

Other funds holding VECT

RCM

Regency Capital Management Honolulu, Hawaii $251M AUM 32.13% 1-Year Est. Return

SOW

State of Wyoming Cheyenne, Wyoming $989M AUM 52.24% 1-Year Est. Return

OrbiMed's VECT Position: Q3 2023 in Review

OrbiMed sold out of VectivBio Holding AG Ordinary Shares (VECT) in Q3 2023, closing a stake of 5,156,561 shares — an estimated $87.7M sold.

OrbiMed first reported a position in VECT in Q2 2021 and held it in 9 quarters. The position peaked at $87.7M in Q2 2023. 2 funds tracked by Wall St. Rank hold VECT as of Q3 2023.

OrbiMed reported no remaining VectivBio Holding AG Ordinary Shares position as of Q3 2023 after selling out during the quarter.
OrbiMed sold 5,156,561 VectivBio Holding AG Ordinary Shares shares in Q3 2023, an estimated $87.7M.
OrbiMed first reported a position in VectivBio Holding AG Ordinary Shares in Q2 2021 and held it in 9 quarters.
OrbiMed's VectivBio Holding AG Ordinary Shares position peaked at $87.7M in Q2 2023.
2 funds tracked by Wall St. Rank held VectivBio Holding AG Ordinary Shares as of Q3 2023.

Based on OrbiMed's 13F filing for Q3 2023, filed 14 Nov 2023.